Orthopaedic supplies

Tender description

The Total Orthopaedic Solutions 2 framework is the second iteration of the successful framework for the provision or orthopaedic goods and services to the NHS which was introduced in 2014. It combines the existing frameworks: total orthopaedic solutions and the DHL MSK framework, to produce a single comprehensive agreement, focused on delivering continued benefits and value to the NHS and its patients. There shall be 10 orthopaedic lots detailed in this notice. The list of eligible entities who may utilise the resulting agreement can be found in this notice within Lot 1 at Sections II.2.4), II.2.11) and Section VI.3) and shall apply to all 10 lots. See Annex A2 of ITT for more detail. Lot 1: hip primary and revision joint replacement including FNOF hemi-arthroplasty and bespoke/custom made implants Sub-Lots: 1.1) Primary hips; 1.2.1) Revision hips; 1.2.2) Revision hips without primary. 1.3) Paediatrics; 1.4) Hemiarthroplasty. (Those entities listed at Section II.2.11) and Section VI.3) are eligible to access the resulting framework including wholly owned companies and subsidiaries during the contract term.) Lot 2: Orthopaedic knee arthroplasty — knee primary and revision joint replacement including bespoke/custom made implants Sub-Lots: 2.1) Primary knees; 2.2a) Revision knees; 2.2b) Revision knees alone; 2.3a) Partial knee link primary; and 2.3b) Partial knee alone. (Those entities listed at Section II.2.11 and Section VI.3) are eligible to access the resulting framework including wholly owned companies and subsidiaries during the contract term.) Lot 3: orthopaedic extremities — shoulder, elbow and ankle joint reconstruction and fracture management through prosthetic implantation, including bespoke/custom made implants. Sub-Lots: 3.1a) Shoulder trauma prosthesis; 3.1b) Shoulder — conventional TSA; 3.1c) Shoulder resurfacing; 3.1d) Shoulder reverse; 3.1e) Shoulder revision; 3.1f) Shoulder humeral reconstruction; 3.2) Elbow; 3.3) Ankle; 3.4) Finger; 3.5) Thumb; 3.6) Wrist; 3.7) Toes. (Those entities listed at Section II.2.11 and Section VI.3) are eligible to access the resulting framework including wholly owned companies and subsidiaries during the contract term.) Lot 4: orthopaedic internal and external fixation — all trauma implants by way of emergency trauma and elective non-recon/congenital correction implants, external fixation devices and consumables. CMF also within this Lot. Sub Lots: 4.1) Core plates; 4.2) DHS; 4.3) Shoulder plating; 4.4) Elbow plates and radial heads; 4.5) Hand and wrist plates; 4.6) Femoral plates; 4.7) Tibial plates; 4.8) Fibular plates; 4.9) Pelvic plates; 4.10) Screws — plate fixation; 4.11) Compression screws; 4.12) Cannulated screws; 4.13) Foot and ankle plates; 4.14) Staples; 4.15) IM nailing systems; 4.16) External fixation systems; 4.17) Paediatrics; 4.18) CMF; 4.19) Thorax; 4.20) Miscellaneous/consumables; 4.21) Instrumentation. (Those entities listed at Section II.2.11) and Section VI.3) are eligible to access the resulting framework including wholly owned companies and subsidiaries during the contract term.) Lot 5: Spine — orthopaedic spinal implants and consumables including spine specific cements and substitutes. (Those entities listed at Section II.2.11 and Section VI.3) are eligible to access the resulting framework including wholly owned companies and subsidiaries during the contract term.) Lot 6: Arthroscopy/sports medicine — all capital and consumable items required for arthroscopic surgery including all stack systems and hardware for resection/ablation, etc. All specialist instrumentation, disposables and implants for soft tissue repair and mobilisation. Sub-Lots: 6.1) Lower limb; 6.2) Anchors; 6.3) Extremity implants; 6.4) Fluid management; 6.5) Shavers; 6.6) RF; 6.7) Specialist instrumentation; 6.8) Capital — visual; 6.9) Capital — surgical; 6.10) Paediatrics. (Those entities listed at Section II.2.11) and Section VI.3) are eligible to access the resulting framework including wholly owned companies and subsidiaries during the contract term.) Lot 7: Bone preparation — bone cement, mixing systems, pulse lavage, bone substitutes, associated products. Sub-Lots: 7.1) Cement; 7.2) Mixing system; 7.3) Preloaded mixing system; 7.4) Pulse lavage; 7.5) Cement plug; 7.6) Temporary spacer; 7.7) Implant removal; 7.8) Bone graft; 7.9) Tourniquet; 7.10) Impaction grafting. (Those entities listed at Section II.2.11) and Section VI.3) are eligible to access the resulting framework including wholly owned companies and subsidiaries during the contract term.) Lot 8: Orthopaedic power tools and consumables — large bone, trauma and high-speed power tools including all loan agreements, maintenance and all associated consumables. Sub-Lots: 8.1a) Hand pieces; 8.1b) Mains chargers; 8.1c) Casing; 8.1d) Adaptors; 8.1e) Attachments; 8.2) Saw blades; 8.3) Drills Burs. (Those entities listed at Section II.2.11) and Section VI.3) are eligible to access the resulting framework including wholly owned companies and subsidiaries during the contract term.) Lot 9: Regenerative technology — all biologic and synthetic bone and soft tissue substitutes and additional products such as platelet separation systems. Sub-Lots: 9.1a) Human soft tissue; 9.1b) Human cancellous bone; 9.1c) Human cancellous/cortical bone; 9.1d) Human head; 9.1e) Human shaft; 9.1f) Human whole bone; 9.1g) Human long bone; 9.1h) Human condyle; 9.1i) Human demineralised bone matrix; 9.1j) Human collagen; 9.2) Animal; 9.3) Synthetic bone void filler; 9.4) Blood products. (Those entities listed at Section II.2.11) and Section VI.3) are eligible to access the resulting framework including wholly owned companies and subsidiaries during the contract term.) Lot 10: Orthopaedic generic instrumentation — all generic operating theatre instrumentation required throughout any orthopaedic procedure; including bone nibblers, retractors, rongeurs, osteotomes, mallets, curettes, etc. Sub-Lots: 10.1) Hoods; 10.2) Toga; 10.3) Ultrasound for bone healing; 10.4) Instruments. (Those entities listed at Section II.2.11) and Section VI.3) are eligible to access the resulting framework including wholly owned companies and subsidiaries during the contract term.)